GBP102.56
0.12% day before yesterday
London, Dec 20, 05:42 pm CET
ISIN
GB0009895292
Symbol
AZN
Sector
Industry

AstraZeneca Stock price

GBP102.56
+2.87 2.88% 1M
-20.66 16.77% 6M
-1.16 1.12% YTD
-0.03 0.03% 1Y
+23.05 28.99% 3Y
+33.39 48.27% 5Y
+69.43 209.54% 10Y
London, Closing price Fri, Dec 20 2024
+0.12 0.12%
ISIN
GB0009895292
Symbol
AZN
Sector
Industry

Key metrics

Market capitalization GBP159.00b
Enterprise Value GBP178.92b
P/E (TTM) P/E ratio 31.05
EV/FCF (TTM) EV/FCF 22.84
EV/Sales (TTM) EV/Sales 4.43
P/S ratio (TTM) P/S ratio 3.94
P/B ratio (TTM) P/B ratio 5.24
Dividend yield 2.22%
Last dividend (FY23) GBP2.28
Revenue growth (TTM) Revenue growth 10.00%
Revenue (TTM) Revenue GBP40.38b
EBIT (operating result TTM) EBIT GBP7.99b
Free Cash Flow (TTM) Free Cash Flow GBP7.83b
Cash position GBP3.68b
EPS (TTM) EPS GBP3.30
P/E forward 23.92
P/S forward 3.78
EV/Sales forward 4.25
Show more

Create a Free Account to create an AstraZeneca alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

AstraZeneca Stock Analysis

Analyst Opinions

32 Analysts have issued a AstraZeneca forecast:

26x Buy
81%
6x Hold
19%

Analyst Opinions

32 Analysts have issued a AstraZeneca forecast:

Buy
81%
Hold
19%

Financial data from AstraZeneca

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
40,380 40,380
10% 10%
100%
- Direct Costs 10,644 10,644
0% 0%
26%
29,736 29,736
14% 14%
74%
- Selling and Administrative Expenses 8,157 8,157
9% 9%
20%
- Research and Development Expense 9,119 9,119
13% 13%
23%
12,460 12,460
19% 19%
31%
- Depreciation and Amortization 4,471 4,471
1% 1%
11%
EBIT (Operating Income) EBIT 7,989 7,989
34% 34%
20%
Net Profit 5,119 5,119
7% 7%
13%

In millions GBP.

Don't miss a Thing! We will send you all news about AstraZeneca directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AstraZeneca Stock News

Neutral
GlobeNewsWire
3 days ago
SAN FRANCISCO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- AstraZeneca PLC (NASDAQ: AZN) is facing a significant crisis in China as authorities there investigate the company for alleged fraud, illegal drug importation, and personal information breaches. The probe has caused AstraZeneca American Depositary Shares to decline sharply and raised serious concerns about the company's business practices in one ...
Neutral
GlobeNewsWire
3 days ago
Dublin, Dec. 19, 2024 (GLOBE NEWSWIRE) -- The "Enterprise Tech Ecosystem Series: AstraZeneca Plc 2024" company profile has been added to ResearchAndMarkets.com's offering.
Neutral
GlobeNewsWire
3 days ago
NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of AstraZeneca PLC (NASDAQ: AZN) resulting from allegations that AstraZeneca may have issued materially misleading business information to the investing public.
More AstraZeneca News

Company Profile

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Head office United Kingdom
CEO Pascal Soriot
Employees 89,900
Founded 1992
Website www.astrazeneca.co.uk

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today